Ticker Details
CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
IPO Date:	October 19, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.75B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.77 | 3.06%
Avg Daily Range (30 D):	$1.24 | 2.41%
Avg Daily Range (90 D):	$1.39 | 2.61%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.43M
Avg Daily Volume (90 D):	1.5M

Trade Size
Avg Trade Size (Sh.):	62
Avg Trade Size (Sh.) (30 D):	54
Avg Trade Size (Sh.) (90 D):	51

Institutional Trades
Total Institutional Trades:	6,848
Avg Institutional Trade:	$2.96M
Avg Institutional Trade (30 D):	$3M
Avg Institutional Trade (90 D):	$2.98M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.83M
Avg Closing Trade (30 D):	$8.45M
Avg Closing Trade (90 D):	$9.09M
Avg Closing Volume:	94K

News

Aug 20, 2026 @ 7:30 PM Vertex Pharmaceuticals' Rally Has a New Engine -- ... Source: Prosper Junior Bakiny

Jul 30, 2026 @ 8:30 PM 3 Stocks With the Most Upside by the End of 2026 Source: James Brumley

Jul 27, 2026 @ 9:25 AM Cathie Wood's Ark Bought $21.3 Million of SpaceX S... Source: Ryan Vanzo

Jul 22, 2026 @ 9:30 AM Cathie Wood's $362 Million CRISPR Therapeutics Bet... Source: James Brumley

Jul 20, 2026 @ 5:30 PM Cathie Wood Is Buying This Up-and-Coming Biotech S... Source: Jeff Siegel

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-4.74	$-.94	$-1.28
Diluted EPS	$-4.74	$-.94	$-1.28
Revenue	$13.39M	$10.18M	$1.46M
Gross Profit
Net Income / Loss	$-451.14M	$-91.15M	$-122.93M
Operating Income / Loss	$-534.34M	$-117.27M	$-130.25M
Cost of Revenue
Net Cash Flow	$94.26M	$-131.98M	$72.27M
PE Ratio